Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD).
COPD
Cardiovascular Disease Reduction
comorbidity
flavonoids
inflammatory disease
pathophysiological mechanisms
rehabilomics.
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
11
2017
revised:
08
03
2018
accepted:
15
03
2018
pubmed:
15
5
2018
medline:
6
2
2020
entrez:
15
5
2018
Statut:
ppublish
Résumé
Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases (CV) Often Coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it hypothesized the treatment of cardiovascular co-morbidities that may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight Secondary Metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point the important effects on CVD risk prevention. This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk. Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases (CV) Often Coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it hypothesized the treatment of cardiovascular co-morbidities that may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight Secondary Metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point the important effects on CVD risk prevention.
OBJECTIVE
OBJECTIVE
This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk.
CONCLUSION
CONCLUSIONS
Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.
Identifiants
pubmed: 29756566
pii: CMC-EPUB-90365
doi: 10.2174/0929867325666180514100640
doi:
Substances chimiques
Cardiovascular Agents
0
Flavonoids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7048-7058Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.